Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026

Amylyx Pharmaceuticals is transitioning from its previous focus on ALS treatments to developing avexitide, a late-stage endocrine drug targeting post-bariatric hypoglycemia, a large orphan market with no approved therapies. The company has $250.8 million in cash, supporting operations through 2028, including the LUCIDITY Phase 3 trial readout expected in late August or early September 2026. If successful, avexitide could launch in 2027, giving Amylyx a first-mover advantage and potential franchise growth without near-term financing risks.